AG
BEAM icon

Algert Global’s Beam Therapeutics BEAM Stock Holding History

Algert Global’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Sell
111,900
-52,392
-32% -$1.58M 0.05% 632
2026
Q1 		$3.92M Buy
164,292
+130,002
+379% +$3.61M 0.06% 508
2025
Q4 		$951K Buy
+34,290
New +$875K 0.01% 859
2025
Q1 		– Sell
-9,378
Closed -$233K – 1186
2024
Q4 		$233K Sell
9,378
-34,145
-78% -$871K 0.01% 1051
2024
Q3 		$1.07M Buy
43,523
+32,130
+282% +$830K 0.03% 735
2024
Q2 		$267K Buy
+11,393
New +$280K 0.01% 1167

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Algert Global's BEAM Position: Q2 2026 in Review

Algert Global reduced its Beam Therapeutics (BEAM) stake by 32% in Q2 2026, selling an estimated $1.58M and leaving 111,900 shares worth $3.84M. The position accounts for 0.05% of the portfolio, ranked #632.

Algert Global first reported a position in BEAM in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.92M in Q1 2026. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Algert Global held 111,900 shares of Beam Therapeutics worth $3.84M as of Q2 2026.
  • Algert Global sold 52,392 Beam Therapeutics shares in Q2 2026, an estimated $1.58M.
  • Beam Therapeutics made up 0.05% of Algert Global's portfolio in Q2 2026, its #632 holding.
  • Algert Global first reported a position in Beam Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Algert Global's Beam Therapeutics position peaked at $3.92M in Q1 2026.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.